The prognostic value of osteopontin expression in non-small cell lung cancer: A meta-analysis

Journal of Molecular Histology

Volumn 45, Issue 5, 2014, Pages 533-540

  Zhang, Tao ^a   Zhang, Dong Ming ^b   Zhao, Da ^a   Hou, Xiao Ming ^a   Liu, Xiao Jun ^a   Ling, Xiao Ling ^a   Ma, Shou Cheng ^a  

^a LANZHOU UNIVERSITY   (China)

^b Pingliang People's Hospital   (China)

Author keywords

Carcinoma; Clinicopathological characteristics; Meta analysis; Non small cell lung; Osteopontin

Indexed keywords

OSTEOPONTIN;

AGE; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER TISSUE; CLINICAL FEATURE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; EMBASE; GENDER; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; SYSTEMATIC REVIEW; TUMOR DIFFERENTIATION; WEB OF SCIENCE; BIOSYNTHESIS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; RISK; TISSUE MICROARRAY; TUMOR VOLUME;

CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM STAGING; ODDS RATIO; OSTEOPONTIN; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR BURDEN;

EID: 84906943985     PISSN: 15672379     EISSN: 15672387     Source Type: Journal    
DOI: 10.1007/s10735-014-9574-3     Document Type: Article

References (46)

1. Alberg AJ, Ford JG, Samet JM (2007) Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132(3 Suppl):29S-55S (Pubitemid 47502798)
2. Ane KR, Marius L, Gisle B et al (2012a) Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer. BMC Cancer 12:333
3. Ane KR, Marius L, Gisle B et al (2012b) Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer. BMC Cancer 12:333
4. Blasberg JD, Pass HI, Goparaju CM et al (2010) Reduction of elevated plasma Osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 28(6):936-941
5. Boldrini L, Donati V, Dell'Omodarme M et al (2005) Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 93(4):453-457 (Pubitemid 43080020)
6. Cao DX, Li ZJ, Jiang XO et al (2012) Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 18(30):3923-3930
7. Chambers AF, Wilson SM, Kerkvliet N et al (1996) Osteopontin expression in lung cancer. Lung Cancer 15(3):311-323 (Pubitemid 26399511)
8. Chang YS, Kim HJ, Chang J et al (2007) Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57(3):373-380 (Pubitemid 47285428)
9. Chen CH, Shiu LY, Su LJ et al (2012) FLJ10540 is associated with tumor progression in nasopharyngeal carcinomas and contributes to nasopharyngeal cell proliferation, and metastasis via osteopontin/CD44 pathway. J Transl Med 10:93
10. Collins LG, Haines C, Perkel R et al (2007) Lung cancer: diagnosis and management. Am Fam Physician 75(1):56-63 (Pubitemid 46064483)
11. Courter D, Cao H, Kwok S et al (2010) The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS ONE 5(3):e9633
12. Davidson B, Holth A, Moripen L et al (2011) Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. Hum Pathol 42(7):991-997
13. Donati V, Boldrini L, Dell'Omodarme M et al (2005) Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11(18):6459-6465 (Pubitemid 41338982)
14. Etiz D, Ataizi FC, Bayman E et al (2013) Prognostic value of osteopontin in patients treated with primary radiotherapy for head and neck cancer. Asian Pac J Cancer Prev 14(9):5175-5178
15. Gui SY, Li HH, Zuo L et al (2007) Protein and mRNA expression of osteopontin in lung cancer and clinical significance thereof. Zhonghua Yi Xue Za Zhi 87(45):3219-3223 (Pubitemid 351350762)
16. Han SS, Lee SJ, Kim WJ et al (2013) Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer. Tuberc Respir Dis (Seoul) 75(3):104-110
17. Hu Z, Lin D, Yuan J et al (2005) Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11(13):4646-4652 (Pubitemid 41557181)
18. Hu Z, Xiao T, Lin DM et al (2007) Over-expression of osteopontin in non-small cell lung cancers: its clinical significance. Zhonghua Zhong Liu Za Zhi 29(8):591-595
19. Isa S, Kawaguchi T, Teramukai S et al (2009) Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 4(9):1104-1110
20. Jema A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90
21. Jin Y, Tong DY, Tang LY et al (2012) Expressions of osteopontin (OPN), amb3 and Pim-1 associated with poor prognosis in non-small cell lung cancer (NSCLC). Chin J Cancer Res 24(2):103-108
22. Joseph S, Harrington R, Walter D et al (2012) Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population. Cancer Biomark 12(4):177-184
23. Karadag F, Gulen ST, Karul AB et al (2011) Osteopontin as a marker of weight loss in lung cancer. Scand J Clin Lab Invest 71(8):690-694
24. Li T, Zhou J, Deng Z et al (2009) Expression of FGF-2 and osteopontin in non-small cell lung cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban 34(11):1114-1119
25. Liang Y, Li H, Hou SC et al (2009) The expression of galectin-3 and osteopontin in occult metastasis of non-small cell lung cancer. Zhonghua Wai Ke Za Zhi 47(14):1061-1063
26. Liang Y, Li H, Hu B et al (2011) Elevated circulating levels of osteopontin are associated with metastasis in advanced non-small cell lung cancer. Chin J Cancer Res 23(1):64-68
27. Mack PC, Redman MW, Chansky K et al (2008) Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 26(29):4771-4776
28. Matušan-Ilijaš K, Damante G, Fabbro D et al (2013) EGFR expression is linked to Osteopontin and Nf-κB signaling in clear cell renal cell carcinoma. Clin Transl Oncol 15(1):65-71
29. Mrochem-Kwarciak J, Mrochen-Domin I, Wojcieszek A et al (2011) Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy. Ginekol Pol 82(12):911-917
30. Ostheimer C, Bache M, Güttler A, et al. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer : Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor. Strahlenther Onkol, 2013, s00066-013-0484-1
31. Rittling SR (2011) Osteopontin in macrophage function. Expert Rev Mol Med 13:e15
32. Rud AK, Boye K, Oijordsbakken M et al (2013) Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer 13(1):540
33. Schneider S, Yochim J, Brabender J et al (2004) Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 10(5):1588-1596 (Pubitemid 38435547)
34. Sim SH, Messenger MP, Gregory WM et al (2012) Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. Br J Cancer 107(7):1131-1137
35. Stemberger C, Matušan-Ilijaš K, Avirović M et al (2013) Osteopontin is associated with decreased apoptosis and av integrin expression in lung adenocarcinoma. Acta Histochem S0065-1281(13):00148
36. Sun BS, Li Y, Zhang ZF et al (2013) Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg 96(6):1943-1951
37. Takenaka M, Hanagiri T, Shinohara S et al (2013) Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. Clin Lung Cancer 14(3):288-294
38. Terpos E, Kiagia M, Karapanagiotou EM et al (2009) The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res 29(5):1651-1657
39. Thorat D, Sahu A, Behera R et al (2013) Association of Osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers. Oncol Lett 6(6):1559-1564
40. Wu J, Zhang X, Zhu YN (2012a) Expression osteopontin and MMP-2 in non-small cell lung cancer. J Clin Exp Pathol 28(8):924-926
41. Wu Y, Jiang W, Wang Y et al (2012b) Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression. PLoS ONE 7(8):e42976
42. Yang Y, Cheng D, Li X et al (2007) Expression and clinicopathological significance of OPN and CD44v6 in lung cancer. Zhongguo Fei Ai Za Zhi 10(2):98-101 (Pubitemid 46658481)
43. Yu J, Pan T, Li J et al (2006) Expression and clinicopathologic significance of OPN, CD44v6 and MMP-2 in squamous cell carcinoma and adenocarcinoma of the lung. Zhongguo Fei Ai Za Zhi 9(4):325-328 (Pubitemid 44306282)
44. Yu TT, Han ZG, Shan L et al (2014) Expression of osteopontin in non-small cell lung cancer and correlative relation with microvascular density. Asian Pac J Cancer Prev 15(1):29-32
45. Zhang X, Xue S, Zheng J et al (2007) Correlation between OPN and P21 in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 10(4):288-290 (Pubitemid 47435166)
46. Zhang Y, Forootan SS, Kamalian L et al (2011) Suppressing tumourigenicity of prostate cancer cells by inhibiting osteopontin expression. Int J Oncol 38(4):1083-1091